FDA Approves Takeda’s First-in-Class Narcolepsy Type 1 Drug

Rare Daily Staff

The U.S. Food and Drug Administration has approved Takeda’s Orzeyful, the first medicine designed to treat the underlying cause of narcolepsy type 1, marking a significant shift in how the rare sleep disorder is managed.

“For too long, people with narcolepsy type 1 have had to manage a complex, lifelong neuropsychiatric condition with treatments that only address pieces of it,” said Tiffany Farchione, director of the Division of Psychiatry within the FDA’s Center for Drug Evaluation and Research. “This new drug is the first medicine that impacts the underlying biology of the disease, treating narcolepsy type 1 as a whole.”

The approval follows clinical studies showing that adults taking the drug experienced meaningful improvements across a wide range of symptoms compared with those receiving placebo.

Patients reported an improved ability to stay awake during the day, fewer sudden muscle weakness episodes, and overall improvements in quality of life. The drug is expected to become available in the United States after a routine review by the Drug Enforcement Administration to determine its controlled substance classification.

Narcolepsy type 1 is a rare, lifelong neurological disorder that affects about 1 in 2,000 people in the United States. It is caused by the loss of brain cells that produce orexin, a chemical that helps regulate wakefulness, sleep cycles, and muscle control. Without orexin, patients struggle to stay awake and maintain normal boundaries between sleep and wake states. Symptoms can include overwhelming daytime sleepiness, sudden loss of muscle tone triggered by emotions, sleep paralysis, vivid dream-like hallucinations, and disrupted nighttime sleep. These symptoms can significantly interfere with work, school, and daily life.

Orzeyful works by directly targeting this underlying biology. It is an oral drug taken twice daily that activates the same brain receptor normally stimulated by orexin, effectively restoring the missing signal. Unlike existing treatments that manage individual symptoms with stimulants or sedatives, this approach aims to address the disorder as a whole. Orzeyful received Breakthrough Therapy Designation and Priority Review from the FDA.

In clinical trials, the therapy showed statistically significant improvements across multiple symptoms and was generally well tolerated. The most common side effects included insomnia, increased urination, and excess saliva.

The approval is based on results from two randomized, double-blind phase 3 studies involving more than 270 adults. Across both studies, patients taking Orzeyful showed improvements in their ability to stay awake during the day compared with those receiving placebo. Patients also reported substantially less daytime sleepiness, a significant reduction in cataplexy episodes, and meaningful improvement across the full spectrum of narcolepsy symptoms, including sleep paralysis, hallucinations, and disrupted nighttime sleep.

Regulators and researchers say the decision represents a turning point for patients who have long relied on treatments that only partially control the condition. Takeda said it plans to make the drug available through specialty pharmacies once federal scheduling is complete, which is expected within about 90 days.